Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.50 |
| ▸ | CNR1 | P21554 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20892856 | 0.82 | HSD17B10 (0.40) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL7161352 | 0.80 | CNR2 (0.58) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL23134820 | 0.79 | CHRNB2 (0.38) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL9070554 | 0.79 | ALDH1A1 (0.37) | MMP1MMP8CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL31336075 | 0.79 | ALDH1A1 (0.37) | MMP1MMP8CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL16135672 | 0.79 | CNR2 (0.54) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL26074486 | 0.78 | CYP2D6 (0.33) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL9715093 | 0.77 | CNR2 (0.53) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL8031100 | 0.77 | ALDH1A1 (0.50) | HPGDSMN1; SMN2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9715091 | 0.77 | CNR2 (0.53) | CNR2CNR1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | Isosterix, Inc. | 2024-05-07 | — | — | US | disclosed |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | Isosterix, Inc. | 2024-05-07 | — | — | US | disclosed |
| WO-2023192817-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2023-09-28 | — | — | US | disclosed |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2023-09-28 | — | — | US | disclosed |
| WO-2022117051-A1 | MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 北京鞍石生物科技有限责任公司 | 2022-06-09 | — | — | WO | disclosed |
| US-11008334-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-13 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| US-8309685-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CNR2 3881/4885CNR1 3348/4885PPARG 2681/4885 |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | KAT6A, KAT6B, KAT2A | CNR2 4846/4885CNR1 4778/4885PPARG 2674/4885 |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CNR2 3425/4885CNR1 3237/4885PPARG 841/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | CNR2 3854/4885CNR1 4228/4885PPARG 3100/4885 |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | KAT6A, KAT6B, KAT2A | CNR2 4846/4885CNR1 4778/4885PPARG 2674/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CNR2 238/4885CNR1 495/4885PPARG 348/4885 |
| US-11008334-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | CNR2 3425/4885CNR1 3237/4885PPARG 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.